In-hospital worsening heart failure in patients admitted for acute heart failure

International Journal of Cardiology

Volumn 225, Issue , 2016, Pages 353-361

  Carubelli, Valentina ^a   Cotter, Gad ^b   Davison, Beth ^b   Gishe, Jemal ^c   Senger, Stefanie ^b   Bonadei, Ivano ^a   Gorga, Elio ^a   Lazzarini, Valentina ^a   Lombardi, Carlo ^a   Metra, Marco ^a  

^a University and Civil Hospital of Brescia   (Italy)

^b Momentum Research Inc   (United States)

^c TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

Acute heart failure; In hospital worsening heart failure; Outcomes; Prognosis

Indexed keywords

ALBUMIN; ASPARTATE AMINOTRANSFERASE; CREATININE; DOPAMINE; HEMOGLOBIN; HYPERTENSIVE AGENT; INOTROPIC AGENT; LOOP DIURETIC AGENT; NITRIC ACID DERIVATIVE; TROPONIN I;

ACUTE HEART FAILURE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HEART FAILURE; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INTRAAORTIC BALLOON PUMP; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LENGTH OF STAY; LIVER DYSFUNCTION; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; NONINVASIVE VENTILATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; SYSTOLIC PULMONARY ARTERY PRESSURE; UREA NITROGEN BLOOD LEVEL; WORSENING HEART FAILURE; ACUTE DISEASE; DEATH; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; TRENDS; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; DEATH; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PATIENT ADMISSION; RETROSPECTIVE STUDIES;

EID: 84992381855     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.10.002     Document Type: Article

References (30)

1. [1] Mebazaa, A., Yilmaz, M.B., Levy, P., Ponikowski, P., Peacock, W.F., Laribi, S., et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur. J. Heart Fail. 17:6 (2015), 544–558.
2. [2] Christ, M., Stork, S., Dorr, M., Heppner, H.J., Muller, C., Wachter, R., et al. Heart failure epidemiology 2000–2013: insights from the German Federal Health Monitoring System. Eur. J. Heart Fail. 18:8 (2016), 1009–1018.
3. [3] Crespo-Leiro, M.G.A.S., Maggioni, A.P., Coats, A.J., Filippatos, G., Ruschitzka, F., Ferrari, R., Piepoli, M.F., Delgado Jimenez, J.F., Metra, M., Fonseca, C., Hradek, J., Amir, O., Logeart, D., Dahlstrom, U., Merkely, B., Drozdz, B., Goncalvesova, E., Hassanein, M., Chioncel, O., Lainscack, M., Seferovic, P.M., Tousoulis, M.A., on behalf of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), European society of cardiology long-term registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. European journal of heart failure, 18(6), 2016, 13.
4. [4] Weatherley, B.D., Milo-Cotter, O., Felker, G.M., Uriel, N., Kaluski, E., Vered, Z., et al. Early worsening heart failure in patients admitted with acute heart failure—a new outcome measure associated with long-term prognosis?. Fundamental & clinical pharmacology. 23:5 (2009), 633–639.
5. [5] Cotter, G., Metra, M., Weatherley, B.D., Dittrich, H.C., Massie, B.M., Ponikowski, P., et al. Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure—association with signs and symptoms, hospitalization duration, and 60-day outcomes. Cardiology 115:1 (2010), 29–36.
6. [6] Packer, M., Colucci, W., Fisher, L., Massie, B.M., Teerlink, J.R., Young, J., et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 1:2 (2013), 103–111.
7. [7] Davison, B.A., Metra, M., Cotter, G., Massie, B.M., Cleland, J.G., Dittrich, H.C., et al. Worsening heart failure following admission for acute heart failure: a pooled analysis of the PROTECT and RELAX-AHF studies. JACC Heart Fail. 3:5 (2015), 395–403.
8. [8] Kelly, J.P., Mentz, R.J., Hasselblad, V., Ezekowitz, J.A., Armstrong, P.W., Zannad, F., et al. Worsening heart failure during hospitalization for acute heart failure: insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). Am. Heart J. 170:2 (2015), 298–305.
9. [9] Mentz, R.J., Metra, M., Cotter, G., Milo, O., McKendry, C., Chiswell, K., et al. Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. Eur. J. Heart Fail. 17:7 (2015), 697–706.
10. [10] Cuffe, M.S., Califf, R.M., Adams, K.F., Benza, R., Bourge, R., Colucci, W.S., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287:12 (2002), 1541–1547.
11. [11] O'Connor, C.M., Gattis, W.A., Adams, K.F. Jr., Hasselblad, V., Chandler, B., Frey, A., et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J. Am. Coll. Cardiol. 41:9 (2003), 1452–1457.
12. [12] McMurray, J.J., Teerlink, J.R., Cotter, G., Bourge, R.C., Cleland, J.G., Jondeau, G., et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298:17 (2007), 2009–2019.
13. [13] Teerlink, J.R., Metra, M., Felker, G.M., Ponikowski, P., Voors, A.A., Weatherley, B.D., et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373:9673 (2009), 1429–1439.
14. [14] Massie, B.M., O'Connor, C.M., Metra, M., Ponikowski, P., Teerlink, J.R., Cotter, G., et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N. Engl. J. Med. 363:15 (2010), 1419–1428.
15. [15] O'Connor, C.M., Starling, R.C., Hernandez, A.F., Armstrong, P.W., Dickstein, K., Hasselblad, V., et al. Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med. 365:1 (2011), 32–43.
16. [16] Felker, G.M., Lee, K.L., Bull, D.A., Redfield, M.M., Stevenson, L.W., Goldsmith, S.R., et al. Diuretic strategies in patients with acute decompensated heart failure. N. Engl. J. Med. 364:9 (2011), 797–805.
17. [17] Teerlink, J.R., Cotter, G., Davison, B.A., Felker, G.M., Filippatos, G., Greenberg, B.H., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381:9860 (2013), 29–39.
18. [18] Chen, H.H., Anstrom, K.J., Givertz, M.M., Stevenson, L.W., Semigran, M.J., Goldsmith, S.R., et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 310:23 (2013), 2533–2543.
19. [19] Butler, J., Gheorghiade, M., Kelkar, A., Fonarow, G.C., Anker, S., Greene, S.J., et al. In-hospital worsening heart failure. Eur. J. Heart Fail. 17:11 (2015), 1104–1113.
20. [20] Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G., Coats, A.J., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 18:8 (2016), 891–975.
21. [21] O'Connor, C.M., Mentz, R.J., Cotter, G., Metra, M., Cleland, J.G., Davison, B.A., et al. The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. Eur. J. Heart Fail. 14:6 (2012), 605–612.
22. [22] Cleland, J.G., Chiswell, K., Teerlink, J.R., Stevens, S., Fiuzat, M., Givertz, M.M., et al. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) study. Circ Heart Fail. 7:1 (2014), 76–87.
23. [23] Voors, A.A., Davison, B.A., Teerlink, J.R., Felker, G.M., Cotter, G., Filippatos, G., et al. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from RELAX-AHF. Eur. J. Heart Fail. 16:11 (2014), 1230–1240.
24. [24] Metra, M., Cotter, G., Davison, B.A., Felker, G.M., Filippatos, G., Greenberg, B.H., et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J. Am. Coll. Cardiol. 61:2 (2013), 196–206.
25. [25] Torre-Amione, G., Milo-Cotter, O., Kaluski, E., Perchenet, L., Kobrin, I., Frey, A., et al. Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome. J. Card. Fail. 15:8 (2009), 639–644.
26. [26] Schrier, R.W., Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail. 1:1 (2008), 2–5.
27. [27] ter Maaten, J.M., Dunning, A.M., Valente, M.A., Damman, K., Ezekowitz, J.A., Califf, R.M., et al. Diuretic response in acute heart failure-an analysis from ASCEND-HF. Am. Heart J. 170:2 (2015), 313–321.
28. [28] Valente, M.A., Voors, A.A., Damman, K., Van Veldhuisen, D.J., Massie, B.M., O'Connor, C.M., et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur. Heart J., 2014.
29. [29] Testani, J.M., Brisco, M.A., Turner, J.M., Spatz, E.S., Bellumkonda, L., Parikh, C.R., et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 7:2 (2014), 261–270.
30. [30] Zannad, F., Garcia, A.A., Anker, S.D., Armstrong, P.W., Calvo, G., Cleland, J.G., et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur. J. Heart Fail. 15:10 (2013), 1082–1094.